Current mechanisms of action in treatment of chronic constipation and irritable bowel syndrome

Lucinda A. Harris

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with, chronic constipation and irritable bowel syndrome (IBS) have a variety of potential treatment options. Treatment typically begins with lifestyle changes and fiber supplementation. The predominant lifestyle changes are alteration of fluid intake, dietary modification, and physical activity. Laxatives constitute the second line of therapy. Patients can avail themselves of various emollient, osmotic, and stimulant laxatives. Among all the laxative agents, the strongest supporting evidence is for lactulose and polyethylene glycol. These conventional therapies have highly variable rates of therapeutic success. Most patients cope with their symptoms and are less than completely satisfied with therapy. Newer therapies have provided additional options that may help improve symptom relief and patient satisfaction. The 5-HT4 serotonin agonist tegaserod has demonstrated efficacy for chronic constipation and constipation-predominant IBS and is approved for treatment of men and women with chronic constipation and for women with IBS. The chloride channel activator lubiprostone recently was approved for treatment of constipation in men and women. The 5-HT3 antagonist alosetron has approval for treatment of diarrhea-predominant IBS in women. A host of investigational agents are in various stages of evaluation and clinical development, many of which represent new approaches to treatment of chronic constipation and IBS.

Original languageEnglish (US)
JournalAdvanced Studies in Medicine
Volume6
Issue number4 A
StatePublished - Apr 2006

Fingerprint

Irritable Bowel Syndrome
Constipation
Laxatives
Therapeutics
Life Style
Serotonin 5-HT4 Receptor Agonists
Emollients
Serotonin 5-HT3 Receptor Antagonists
Diet Therapy
Lactulose
Serotonin Receptor Agonists
Patient Satisfaction
Diarrhea
Exercise

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current mechanisms of action in treatment of chronic constipation and irritable bowel syndrome. / Harris, Lucinda A.

In: Advanced Studies in Medicine, Vol. 6, No. 4 A, 04.2006.

Research output: Contribution to journalArticle

@article{d051bade3c8d4d328da10ccd8d68feee,
title = "Current mechanisms of action in treatment of chronic constipation and irritable bowel syndrome",
abstract = "Patients with, chronic constipation and irritable bowel syndrome (IBS) have a variety of potential treatment options. Treatment typically begins with lifestyle changes and fiber supplementation. The predominant lifestyle changes are alteration of fluid intake, dietary modification, and physical activity. Laxatives constitute the second line of therapy. Patients can avail themselves of various emollient, osmotic, and stimulant laxatives. Among all the laxative agents, the strongest supporting evidence is for lactulose and polyethylene glycol. These conventional therapies have highly variable rates of therapeutic success. Most patients cope with their symptoms and are less than completely satisfied with therapy. Newer therapies have provided additional options that may help improve symptom relief and patient satisfaction. The 5-HT4 serotonin agonist tegaserod has demonstrated efficacy for chronic constipation and constipation-predominant IBS and is approved for treatment of men and women with chronic constipation and for women with IBS. The chloride channel activator lubiprostone recently was approved for treatment of constipation in men and women. The 5-HT3 antagonist alosetron has approval for treatment of diarrhea-predominant IBS in women. A host of investigational agents are in various stages of evaluation and clinical development, many of which represent new approaches to treatment of chronic constipation and IBS.",
author = "Harris, {Lucinda A.}",
year = "2006",
month = "4",
language = "English (US)",
volume = "6",
journal = "Advanced Studies in Medicine",
issn = "1530-3004",
publisher = "Galen Publishing LLC",
number = "4 A",

}

TY - JOUR

T1 - Current mechanisms of action in treatment of chronic constipation and irritable bowel syndrome

AU - Harris, Lucinda A.

PY - 2006/4

Y1 - 2006/4

N2 - Patients with, chronic constipation and irritable bowel syndrome (IBS) have a variety of potential treatment options. Treatment typically begins with lifestyle changes and fiber supplementation. The predominant lifestyle changes are alteration of fluid intake, dietary modification, and physical activity. Laxatives constitute the second line of therapy. Patients can avail themselves of various emollient, osmotic, and stimulant laxatives. Among all the laxative agents, the strongest supporting evidence is for lactulose and polyethylene glycol. These conventional therapies have highly variable rates of therapeutic success. Most patients cope with their symptoms and are less than completely satisfied with therapy. Newer therapies have provided additional options that may help improve symptom relief and patient satisfaction. The 5-HT4 serotonin agonist tegaserod has demonstrated efficacy for chronic constipation and constipation-predominant IBS and is approved for treatment of men and women with chronic constipation and for women with IBS. The chloride channel activator lubiprostone recently was approved for treatment of constipation in men and women. The 5-HT3 antagonist alosetron has approval for treatment of diarrhea-predominant IBS in women. A host of investigational agents are in various stages of evaluation and clinical development, many of which represent new approaches to treatment of chronic constipation and IBS.

AB - Patients with, chronic constipation and irritable bowel syndrome (IBS) have a variety of potential treatment options. Treatment typically begins with lifestyle changes and fiber supplementation. The predominant lifestyle changes are alteration of fluid intake, dietary modification, and physical activity. Laxatives constitute the second line of therapy. Patients can avail themselves of various emollient, osmotic, and stimulant laxatives. Among all the laxative agents, the strongest supporting evidence is for lactulose and polyethylene glycol. These conventional therapies have highly variable rates of therapeutic success. Most patients cope with their symptoms and are less than completely satisfied with therapy. Newer therapies have provided additional options that may help improve symptom relief and patient satisfaction. The 5-HT4 serotonin agonist tegaserod has demonstrated efficacy for chronic constipation and constipation-predominant IBS and is approved for treatment of men and women with chronic constipation and for women with IBS. The chloride channel activator lubiprostone recently was approved for treatment of constipation in men and women. The 5-HT3 antagonist alosetron has approval for treatment of diarrhea-predominant IBS in women. A host of investigational agents are in various stages of evaluation and clinical development, many of which represent new approaches to treatment of chronic constipation and IBS.

UR - http://www.scopus.com/inward/record.url?scp=33646449485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646449485&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33646449485

VL - 6

JO - Advanced Studies in Medicine

JF - Advanced Studies in Medicine

SN - 1530-3004

IS - 4 A

ER -